Autism Spectrum Disorder
Clinical Snapshot
Autism spectrum disorder (ASD) is a neurodevelopmental condition defined by persistent differences in social communication and social interaction, together with restricted, repetitive patterns of behaviour, interests, or activities, present from early in development and causing clinically significant functional impact.[1]
No medication treats autism itself. There is no pharmacologic cure for ASD, and no drug reliably improves its core features — social-communication differences and restricted or repetitive behaviours and interests.[2] The foundation of care is behavioural, developmental, and educational intervention, most commonly applied behaviour analysis (ABA) and related evidence-based programs, started as early as possible and continued for as long as it remains beneficial.[1] Pharmacotherapy has a real but strictly adjunctive role: treating one specific, clearly identified, functionally impairing symptom that co-occurs with ASD — irritability with aggression or self-injury, overlapping ADHD-type symptoms, anxiety or a rigid/repetitive-behaviour flare, or sleep difficulty — never the diagnosis of autism itself.[2]
This chapter is organized by target symptom rather than by drug class, because that is how a prescriber and pharmacist should actually approach a patient with ASD being considered for medication: identify the specific symptom causing impairment, confirm behavioural/educational treatment is already in place, rule out a medical or environmental cause of the behaviour, and only then select an agent matched to that one target.
Recognize the Condition
ASD is diagnosed clinically by a qualified specialist — a developmental pediatrician, child and adolescent psychiatrist, or psychologist — using structured history and observation; there is no laboratory or imaging test that confirms it. Diagnostic criteria require persistent deficits in social communication and social interaction across multiple contexts; restricted, repetitive patterns of behaviour, interests, or activities; symptoms present from early in the developmental period, though they may not become fully apparent until social demands exceed capacity; and clinically significant impairment that is not better explained by intellectual disability or global developmental delay alone.[1]
Severity and presentation vary enormously across the spectrum, from a person requiring very substantial support with minimal or no spoken language, to a person who is independently verbal with subtler social-communication differences. Co-occurring intellectual disability, language impairment, epilepsy, gastrointestinal symptoms, sleep disorders, and psychiatric conditions — ADHD, anxiety, depression, obsessive-compulsive-like presentations — are common and actively shape both the clinical picture and treatment planning.[2]
The 4 target-symptom domains pharmacotherapy actually addresses
Irritability, aggression, and self-injury
Severe tantrums, aggression toward others, or self-injurious behaviour causing functional impairment or a safety risk. The best-studied target in ASD, and the only one with agents carrying a specific regulatory approval anywhere.[3]
Overlapping ADHD-type symptoms
Inattention, hyperactivity, and impulsivity meeting a genuine co-occurring ADHD picture — extremely common in ASD and managed largely per the Attention-Deficit Hyperactivity Disorder chapter of this library, with the ASD-specific caveats below.
Anxiety and rigid or repetitive-behaviour flares
Debilitating anxiety, or a significant escalation in rigid, ritualistic, or repetitive behaviour. Genuinely present as a target, but the pharmacologic evidence base here is the weakest of the 4 domains.[4]
Sleep-onset and sleep-maintenance difficulty
Sleep problems affect a large majority of children with ASD and often independently drive daytime irritability, inattention, and family strain. The best-evidenced pharmacologic target in this specific population.[5]
Risk Factors
- A first-degree relative with ASD — the single strongest known risk factor.
- Older parental age at conception (both maternal and paternal).
- Prematurity or very low birth weight.
- Prenatal exposure to certain medications, most notably valproate.
- A co-occurring genetic condition — for example, fragile X syndrome, tuberous sclerosis complex, or a chromosomal microdeletion/microduplication syndrome.
- Male sex — ASD is diagnosed several times more often in males, though under-recognition in females, who often present with subtler or better-camouflaged social difficulties, is increasingly recognized as a contributor to this gap.
- A sibling already diagnosed with ASD.
Red Flags & Refer
Most ASD-related pharmacotherapy is planned and non-urgent, but escalate promptly for any of the following:
- Severe self-injury or aggression posing an immediate safety risk to the patient or others — urgent psychiatric or crisis assessment, not a routine medication adjustment.
- A sudden, unexplained change in behaviour or a regression in previously stable functioning. Always investigate for an underlying medical cause before treating this as a primary behavioural or psychiatric escalation — in a nonverbal or minimally-verbal patient, pain, constipation, gastroesophageal reflux, a dental abscess, an ear infection, a headache or migraine, menstrual pain, an occult fracture, or a new seizure disorder can present as nothing but a change in behaviour.
- New or worsening suicidal thoughts or behaviour. Screen actively even when communication differences make this harder to elicit — suicide risk in ASD, particularly in verbally fluent adolescents and adults, is real and historically under-recognized.
- New psychotic symptoms — hallucinations, paranoia, or disorganized thinking clearly outside the patient's baseline.
- Catatonia — immobility, mutism, unusual posturing, negativism, or refusal to eat or drink. A real, under-recognized, and potentially life-threatening risk in ASD adolescents and adults that needs urgent psychiatric assessment.
- Signs of neuroleptic malignant syndrome — fever, muscle rigidity, autonomic instability, or altered consciousness in a patient on risperidone or aripiprazole. Stop the antipsychotic and refer for emergency assessment.
- Severe or rapidly worsening extrapyramidal symptoms, or any sign of tardive dyskinesia (repetitive, involuntary movements of the face, tongue, or limbs).
- A significant new metabolic abnormality on monitoring — a rapidly rising weight trajectory or new hyperglycemia.
- Priapism — a recognized, though rare, adverse effect of risperidone and aripiprazole.
- Symptoms suggestive of serotonin syndrome if an SSRI is combined with another serotonergic medication.
Assessment & Diagnosis
Before considering any medication
Confirm the ASD diagnosis was made by a qualified specialist, confirm behavioural and educational intervention is already in place or actively being arranged, and identify the one specific target symptom causing functional impairment — medication is never started to treat "autism" as a whole.[2]
Rule out a medical or environmental cause of the behaviour first
This step is the single most important, and most often skipped, part of assessment in a nonverbal or minimally-verbal patient — behaviour is frequently the only way an unmet need or a source of pain is communicated.
| What can look like the target symptom | What actually distinguishes it |
|---|---|
| Occult pain — dental, musculoskeletal, headache/migraine, otitis media, menstrual | A recent onset tied to a specific body area on examination; resolves once the pain source is treated rather than with a behavioural or psychotropic intervention. |
| Gastrointestinal contributors — constipation, gastroesophageal reflux | Very common in ASD and easily missed; a focused GI history and abdominal examination, and a trial of standard GI treatment, should precede escalating psychotropic therapy for a new irritability pattern. |
| An untreated sleep disorder, including obstructive sleep apnea | Daytime irritability and inattention that track closely with poor sleep quality; a sleep history, and treatment of the sleep problem itself, often resolves the daytime symptom without any other medication. |
| An environmental or sensory trigger, or a routine disruption | Behaviour tied to a specific, identifiable antecedent (a schedule change, a new setting, sensory overload) rather than a pervasive, unprovoked pattern; addressed through the behavioural-support plan, not medication. |
| A medication adverse effect already being taken for another reason | Temporal relationship to a recent medication start or dose change. |
| A new seizure disorder | Episodic behaviour change with associated motor, staring, or awareness features; obtain a careful seizure history and refer for EEG if suspected — epilepsy is substantially more common in ASD than in the general population. |
| A genuine, functionally impairing target symptom (irritability/aggression/self-injury, ADHD-overlap symptoms, anxiety/repetitive-behaviour flare, or sleep difficulty) persisting despite behavioural intervention and with no medical/environmental cause found | This is the only category where pharmacotherapy, matched to the specific target, is appropriate. |
Baseline assessment before starting risperidone or aripiprazole
Baseline assessment before starting a stimulant, atomoxetine, an SSRI, or melatonin
Follow the Attention-Deficit Hyperactivity Disorder chapter's cardiovascular screening approach in full before a stimulant or atomoxetine. Before an SSRI, screen for a personal or family history of bipolar disorder, since activation and mood switching are real risks. Before melatonin, take a focused sleep history or a brief sleep diary to confirm the difficulty is genuinely sleep-onset or sleep-maintenance in nature, and to distinguish it from a behavioural bedtime-resistance pattern that behavioural strategies alone may resolve.
Treatment Targets
- Reduce the severity and frequency of the one identified target symptom — irritability/aggression/self-injury, ADHD-overlap symptoms, anxiety/repetitive-behaviour flares, or sleep difficulty — enough to meaningfully improve daily functioning and safety.
- Improve the patient's ability to participate in and benefit from ongoing behavioural and educational intervention, which medication supports but never replaces.
- Minimize adverse effects by using the lowest effective dose, and by reassessing the ongoing need for any psychotropic medication at planned intervals rather than continuing it indefinitely by default.
- Support caregiver and family functioning and quality of life.
- Never expect medication to improve core social-communication differences or restricted/repetitive interests — that is not a realistic or appropriate treatment target for any agent in this chapter.[2]
Choose Initial Treatment
Irritability, aggression, or self-injury
1st line behavioural intervention, plus ruling out a medical/environmental cause, before any medication is considered. If moderate-to-severe symptoms persist with clear functional impairment: risperidone or aripiprazole — the only 2 agents with a specific regulatory approval for this indication (FDA-approved; Health Canada has not issued an ASD-specific indication for either, so this remains off-label in Canada despite the strength of the evidence).[3][2]
Overlapping ADHD-type symptoms
Alternative — use when a genuine co-occurring ADHD picture (inattention, hyperactivity, impulsivity) is causing functional impairment: methylphenidate is the reasonable initial choice, started below the standard ADHD starting dose given a lower response rate and higher rate of adverse-effect-related discontinuation than in typically-developing ADHD.[6] Atomoxetine is a reasonable alternative when a stimulant is not tolerated or when prominent anxiety makes a stimulant's activating effect undesirable. See the Attention-Deficit Hyperactivity Disorder chapter for the full approach.
Anxiety and rigid or repetitive-behaviour flares
Special situation an SSRI (sertraline or fluoxetine) may be trialed cautiously for genuinely debilitating anxiety, but the evidence base is the weakest of the 4 domains — a well-designed placebo-controlled trial found citalopram no more effective than placebo for repetitive behaviour specifically, with significantly more adverse effects.[4] Reserve for real functional impairment rather than routine use, start at a low dose, titrate slowly, and monitor closely for activation or behavioural disinhibition, which appears more common in ASD than in typically-developing youth.
Sleep-onset or sleep-maintenance difficulty
1st line sleep hygiene and behavioural sleep strategies. 1st-line pharmacologic option melatonin if behavioural strategies alone are insufficient — the best-evidenced agent in this entire chapter for this specific population, and the only target-symptom domain with a Health Canada-approved product (a prolonged-release formulation) developed and studied specifically for ASD-associated insomnia.[5]
Why this chapter is organized by target symptom, not by drug class
Every agent below treats one symptom, not autism
Risperidone and aripiprazole do not improve core social-communication features. Stimulants and atomoxetine treat co-occurring ADHD symptoms, not autism. SSRIs treat co-occurring anxiety, not autism. Melatonin treats sleep, not autism. Label every prescription, and every counselling conversation, by its actual target.
Behavioural/educational intervention never stops
Starting medication for one target symptom is never a reason to reduce or replace ongoing ABA or other behavioural/educational intervention — the 2 are complementary, not alternatives.
Non-Pharmacologic Treatment
- Applied behaviour analysis (ABA) and related evidence-based behavioural/developmental interventions (for example, the Early Start Denver Model in young children) are the foundation of ASD care at every age and for every target symptom — started as early as possible, individualized to the patient, and continued for as long as they remain beneficial.[1]
- Speech-language therapy and occupational therapy, including sensory-based strategies, support communication and daily functioning and are frequently combined with behavioural intervention.
- Special education services and an individualized education plan support functioning independent of medication status.
- Parent-mediated intervention training teaches caregivers to reinforce communication and behavioural strategies consistently across settings, and is itself an evidence-based intervention rather than only a support for the child's own therapy.
- Structured environment and visual supports — predictable routines, visual schedules, clear transition warnings — reduce the environmental and sensory triggers that often precipitate irritability or anxiety.
- Sleep-hygiene and behavioural sleep strategies (a consistent bedtime routine, a calming pre-bed routine, limiting evening screen time, addressing anxiety or sensory contributors to bedtime resistance) should be tried, and continued, before and alongside melatonin — melatonin supplements rather than replaces this step.
- Cognitive-behavioural therapy, adapted for developmental level and communication style, has evidence for anxiety in verbally fluent patients with ASD and is a reasonable adjunct or alternative to an SSRI trial.
- Combining behavioural and pharmacologic treatment, when medication is genuinely indicated for a specific target symptom, is more effective than either approach alone — present the two as complementary, never as alternatives.[1]
Special Populations
Pediatric
Almost every agent in this chapter is dosed and monitored differently in children than in adults; formulation-specific pediatric dosing is detailed in the Pharmacologic Treatment Options and Drug Tables sections. Children and adolescents with ASD are frequently more sensitive to both the therapeutic and adverse effects of psychotropic medication than typically-developing peers — start low and titrate more slowly than the standard dose for the same agent used outside ASD.[2]
Adults with ASD
Irritability, aggression, self-injury, and anxiety can persist into adulthood, and the same target-symptom approach applies. The antipsychotic and SSRI evidence base specific to adults with ASD is smaller than the pediatric evidence base; individualize with specialist input. Because these medications are often started in childhood, actively reassess the ongoing need for continued therapy at each follow-up rather than assuming indefinite continuation is appropriate.
Communication differences — a distinct counselling population
A nonverbal or minimally-verbal patient cannot reliably report a side effect, a symptom of hyperprolactinemia, or a swallowing difficulty with a specific formulation — caregiver-completed standardized behaviour scales (see Monitoring & Follow-Up) and structured caregiver questioning at every visit are not optional extras here, they are the primary way adverse effects and efficacy are actually detected. Administration itself is frequently a genuine barrier independent of "adherence" in the usual sense — taste, texture, swallowing difficulty, and disruption of a fixed routine can all prevent a clinically appropriate medication from actually being taken; see the Clinical Decision Algorithm and Common Errors to Avoid sections for the practical approach.
Intellectual disability
Common alongside ASD and independently increases sensitivity to medication effects, both therapeutic and adverse — apply the same "start low, go slow" principle even more conservatively when significant intellectual disability co-occurs.
Pregnancy and breastfeeding
Monitoring & Follow-Up
Reassessing ongoing need
For every agent in this chapter, periodically reassess whether the target symptom, the behavioural context, and the patient's overall functioning still support continued medication — a planned dose reduction or discontinuation trial, done gradually and with the behavioural/educational team's input, is appropriate once the target symptom has been stable for a meaningful period, rather than continuing therapy indefinitely by default.
Common Errors to Avoid
- Starting or escalating medication to treat "autism" broadly, rather than one specific, clearly identified target symptom — there is no such thing as an "autism dose" of anything in this chapter.
- Expecting risperidone, aripiprazole, a stimulant, an SSRI, or melatonin to improve core social-communication or restricted/repetitive-interest features — none of them do.[2]
- Attributing a new or worsening behaviour entirely to autism without first ruling out an occult medical cause — pain, constipation, GERD, dental pain, a seizure, or a sleep disorder — especially in a nonverbal or minimally-verbal patient.
- Starting risperidone or aripiprazole without a documented specific target symptom and the required baseline metabolic and movement assessment.
- Assuming Health Canada has approved risperidone or aripiprazole for this indication — it has not; both are used off-label in Canada, and that should be part of the informed-consent conversation.
- Discontinuing or reducing behavioural/educational intervention once medication is started, rather than continuing both together.
- Using an adult or typically-developing-ADHD starting dose in a small child, or in a patient with ASD generally, without adjusting for the population's greater medication sensitivity.
- Missing prolactin-related, extrapyramidal, or GI symptoms because a minimally-verbal patient did not spontaneously report them — ask the caregiver directly and specifically at every visit rather than waiting for a complaint.
- Treating a genuine SSRI-associated activation or behavioural disinhibition episode as "the underlying anxiety getting worse" rather than as a medication effect requiring dose reassessment.
- Not reassessing the ongoing need for a long-continued antipsychotic, stimulant, SSRI, or melatonin prescription — these are frequently started in childhood and can persist for years without a formal re-evaluation.
- Assuming poor adherence reflects refusal rather than a genuine, fixable administration barrier — taste, texture, swallowing difficulty, or disruption of a fixed routine (see Special Populations and the Clinical Decision Algorithm).
Clinical Decision Algorithm
Drug Tables
How to use this table: every drug class below is grouped by the specific target symptom it treats, never by "autism treatment" generally — none of these agents improve core social-communication or restricted/repetitive-interest features. Doses require patient-specific confirmation. Select any drug name to open its complete Pharmasist Drug Database page.
Second-generation antipsychotics — irritability, aggression, and self-injury
The only 2 agents with a specific regulatory approval for an ASD-associated target symptom anywhere; both remain off-label in Canada since Health Canada has not issued an autism-specific indication for either.
| Drug | Dosage | Frequency | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|---|
| Risperidone | Weight under 20 kg: Start 0.25 mg PO once daily; may increase to 0.5 mg once daily after a minimum of 4 days; further 0.25 mg increases no more often than every 2 weeks if needed Weight 20-45 kg: Start 0.5 mg PO once daily; may increase to 1 mg once daily after a minimum of 4 days; further 0.5 mg increases no more often than every 2 weeks; usual effective range 0.5-2.5 mg per day Weight over 45 kg: Same titration; usual effective range 0.5-3.5 mg per day | Once daily, or divided twice daily | Weight gain, increased appetite, sedation, fatigue, drooling, dose-related extrapyramidal symptoms, hyperprolactinemia (galactorrhea, gynecomastia, menstrual irregularity — generally more prominent than with aripiprazole) | Strong CYP2D6/3A4 inhibitors (fluoxetine, paroxetine, clarithromycin) raise levels significantly. Strong CYP3A4 inducers (carbamazepine, rifampin, phenytoin) can substantially lower levels. Additive sedation with other CNS depressants. | FDA-approved for irritability associated with autistic disorder in children and adolescents 5-16 years — the best-studied agent for this indication. Not Health Canada-approved for this indication. |
| Aripiprazole | Starting dose: 2 mg PO once daily Titration: Increase to 5 mg once daily after a minimum of 1 week; further 5 mg increases at intervals of at least 1 week if needed Usual effective range: 5-15 mg per day | Once daily | Sedation, akathisia and other extrapyramidal symptoms, weight gain (generally less than risperidone), GI upset, headache; less prolactin elevation than risperidone | CYP2D6/3A4 substrate — strong inhibitors (fluoxetine, paroxetine, ketoconazole) roughly double exposure and generally require a dose reduction; strong inducers (carbamazepine, rifampin) roughly halve exposure and may require a dose increase over about 2 weeks, per the product monograph. | FDA-approved for irritability associated with autistic disorder in children and adolescents 6-17 years; acts somewhat faster and generally causes less sedation, weight gain, and prolactin elevation than risperidone. Not Health Canada-approved for this indication. |
Stimulant and non-stimulant agents — overlapping ADHD-type symptoms
Full dosing, titration, cardiovascular screening, and monitoring is in the Attention-Deficit Hyperactivity Disorder chapter and applies largely unchanged here; the notes below cover only what genuinely differs because the patient also has ASD.
| Drug | Dosage | Frequency | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|---|
| Methylphenidate | Starting approach: Start below the standard ADHD starting dose (see the Attention-Deficit Hyperactivity Disorder chapter) and titrate more slowly | See the Attention-Deficit Hyperactivity Disorder chapter for formulation-specific dosing | Appetite suppression, insomnia, irritability, headache — the same adverse-effect profile as in typically-developing ADHD, but more frequent and more likely to prompt discontinuation | Same interactions as in the Attention-Deficit Hyperactivity Disorder chapter. | In a randomized, controlled, crossover trial specific to this population, about half of participants responded to methylphenidate, a lower response rate than in typically-developing ADHD, and adverse effects led to discontinuation in nearly 1 in 5. Start below the standard ADHD starting dose and titrate in smaller increments. |
| Atomoxetine | Dosing: As in the Attention-Deficit Hyperactivity Disorder chapter | See the Attention-Deficit Hyperactivity Disorder chapter for full dosing | Same as in the Attention-Deficit Hyperactivity Disorder chapter | Same as in the Attention-Deficit Hyperactivity Disorder chapter. | A reasonable alternative when a stimulant is not tolerated, when prominent anxiety makes a stimulant's activating effect undesirable, or when diversion risk favours a non-controlled option; ASD-specific evidence is more limited than in typically-developing ADHD. |
Selective serotonin reuptake inhibitors — anxiety and rigid/repetitive-behaviour flares
The weakest evidence base of the 4 target-symptom domains in this chapter — reserve for genuinely debilitating anxiety rather than routine use.
| Drug | Dosage | Frequency | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|---|
| Sertraline | Starting dose (children): 12.5-25 mg PO once daily Titration: Increase gradually, no faster than every 1-2 weeks, based on response and tolerability | Once daily; requires several weeks for full effect | GI upset, activation/behavioural disinhibition (watch specifically for new or worsening agitation, irritability, or self-injury after starting — this appears more common in ASD than in typically-developing youth), sexual dysfunction, sweating | Caution with other serotonergic drugs (serotonin syndrome risk). | A well-designed placebo-controlled trial found the related SSRI citalopram no more effective than placebo for repetitive behaviour specifically, with significantly more adverse effects. Start at a low dose, titrate slowly, and reserve for real functional impairment. |
| Fluoxetine | Starting dose (children): Start at the lowest available dose and titrate gradually based on response and tolerability | Once daily; long half-life | Same activation/disinhibition caution as sertraline; GI upset, sexual dysfunction, insomnia | Potent CYP2D6 inhibitor — check for an interaction with other CYP2D6-metabolized drugs, including risperidone and aripiprazole, if co-prescribed; long half-life delays washout when switching agents. | An alternative SSRI with the same evidence caveats as sertraline; the long half-life is forgiving of an occasional missed dose, a genuine practical advantage for a patient with administration challenges. |
Melatonin — sleep-onset and sleep-maintenance difficulty
The best-evidenced target-symptom domain in this chapter for this specific population.
| Drug | Dosage | Frequency | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|---|
| Melatonin, prolonged-release (Slenyto) | Starting dose: 2 mg once daily Titration: If response is inadequate, increase to 5 mg once daily, then to a maximum of 10 mg once daily, reassessing effect every 2-3 weeks | Once daily, 30-60 minutes before bedtime, with or after food | Generally well tolerated; morning drowsiness, headache; uncommon mood or behaviour change | Additive sedation with other CNS depressants; fluvoxamine can raise melatonin levels. | Received a Health Canada Notice of Compliance specifically for insomnia in children and adolescents aged 2 to under 18 years with ASD and/or Smith-Magenis syndrome, where sleep hygiene alone has been insufficient — the first, and as of authoring the only, medication with a Health Canada indication specifically for an ASD-associated symptom. Dosing is not weight- or age-based within the approved age range. |
| Melatonin, standard immediate-release (non-prescription) | Starting dose: 1-3 mg once daily Titration: Increase by 1-3 mg every 1-2 weeks if needed, to a maximum of about 10 mg per day | Once daily, 30-60 minutes before bedtime | Same as above | Same as above. | A reasonable, lower-cost alternative where the prescription prolonged-release product is unavailable or not covered; evidence supports both sleep-onset and, to a lesser extent, sleep-maintenance benefit in this population. |
Evidence note: regulatory status, dosing, and comments above reflect current FDA/Health Canada approvals and primary literature, cross-checked against CPS and AACAP guidance.[1][2][3][4][6][5]
References
- Post-diagnostic management and follow-up care for autism spectrum disorder — Canadian Paediatric Society, Autism Spectrum Disorder Guidelines Task Force (Ip A, Zwaigenbaum L, Brian JA). Paediatr Child Health 2019;24(7):461-468
- Practice Parameter for the Assessment and Treatment of Children and Adolescents With Autism Spectrum Disorder — American Academy of Child and Adolescent Psychiatry, Committee on Quality Issues (Volkmar F, Siegel M, Woodbury-Smith M, King B, McCracken J, State M). J Am Acad Child Adolesc Psychiatry 2014;53(2):237-257
- Risperidone in Children with Autism and Serious Behavioral Problems — New England Journal of Medicine, Research Units on Pediatric Psychopharmacology Autism Network (McCracken JT, McGough J, Shah B, et al.). N Engl J Med 2002;347(5):314-321
- Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior — Archives of General Psychiatry, STAART Psychopharmacology Network (King BH, Hollander E, Sikich L, et al.). Arch Gen Psychiatry 2009;66(6):583-590
- Health Canada Approves Slenyto — Extended-Release Melatonin Formulation — as a Prescription Drug for Insomnia in Children with Autism Spectrum Disorder and Smith-Magenis Syndrome — Neurim Pharmaceuticals. Neurim Pharmaceuticals press release, Health Canada Notice of Compliance issued September 8, 2025
- Randomized, Controlled, Crossover Trial of Methylphenidate in Pervasive Developmental Disorders With Hyperactivity — Archives of General Psychiatry, Research Units on Pediatric Psychopharmacology Autism Network (Posey DJ, Aman MG, Arnold LE, et al.). Arch Gen Psychiatry 2005;62(11):1266-1274
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.